We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+1.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$6.63B
AUM Growth
-$522M
Cap. Flow
-$72.7M
Cap. Flow %
-1.1%
Top 10 Hldgs %
50.25%
Holding
100
New
18
Increased
9
Reduced
13
Closed
18

Top Buys

Rank Stock Value
1
VOR icon
Vor Biopharma
VOR
+$470M
2
TIL icon
Instil Bio
TIL
+$125M
3
MCRB icon
Seres Therapeutics
MCRB
+$85.1M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$84.8M
5
ASND icon
Ascendis Pharma A/S
ASND
+$83.1M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$312M
2
TGTX icon
TG Therapeutics
TGTX
+$195M
3
NVAX icon
Novavax
NVAX
+$157M
4
KROS icon
Keros Therapeutics
KROS
+$132M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$73.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.53%
2 Financials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTMX icon
51
CytomX Therapeutics
CTMX
$723M
$27.1M 0.41%
+3,500,000
New +$27.7M
ACHL
52
DELISTED
Achilles Therapeutics
ACHL
$23M 0.35%
+1,388,888
New +$23M
SNDX icon
53
Syndax Pharmaceuticals
SNDX
$1.69B
$22.9M 0.34%
1,023,067
– –
LRMR icon
54
Larimar Therapeutics
LRMR
$427M
$22.1M 0.33%
1,515,151
– –
IMA
55
ImageneBio Inc
IMA
$64.9M
$21.2M 0.32%
+62,500
New +$21.4M
SCPH
56
DELISTED
scPharmaceuticals
SCPH
$18.2M 0.27%
2,731,170
-787,828
-22% -$5.4M
CNCE
57
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$15.1M 0.23%
3,033,603
+1,210,083
+66% +$9.78M
CGEM icon
58
Cullinan Oncology
CGEM
$1.08B
$14.6M 0.22%
+350,000
New +$14.2M
ORIC icon
59
Oric Pharmaceuticals
ORIC
$1.39B
$14.3M 0.22%
584,000
– –
PRQR icon
60
ProQR Therapeutics
PRQR
$258M
$14M 0.21%
+2,117,669
New +$10.8M
TNGX icon
61
Tango Therapeutics
TNGX
$4.78B
$13.9M 0.21%
1,250,000
– –
NAUT icon
62
Nautilus Biotechnolgy
NAUT
$125M
$13.4M 0.2%
971,430
-28,570
-3% -$396K
BLSA
63
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$13.2M 0.2%
1,250,000
– –
MIST icon
64
Milestone Pharmaceuticals
MIST
$146M
$13M 0.2%
2,246,503
-81,211
-3% -$594K
EYPT icon
65
EyePoint Inc
EYPT
$978M
$12.7M 0.19%
+1,250,000
New +$14.1M
RPTX
66
DELISTED
Repare Therapeutics
RPTX
$12.6M 0.19%
409,000
– –
OCUL icon
67
Ocular Therapeutix
OCUL
$1.89B
$12.3M 0.19%
750,000
– –
ARYD
68
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$10.5M 0.16%
+1,000,000
New +$10.8M
TXMD icon
69
TherapeuticsMD
TXMD
$23.6M
$10.5M 0.16%
156,250
– –
FLACU
70
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
$10.2M 0.15%
1,000,000
– –
PRDS
71
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$9.96M 0.15%
+1,000,000
New +$10.3M
PHAS
72
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$9.86M 0.15%
+2,850,000
New +$11.6M
COGT icon
73
Cogent Biosciences
COGT
$7.32B
$9.01M 0.14%
1,025,641
– –
KALV
74
DELISTED
KalVista Pharmaceuticals
KALV
$8.99M 0.14%
+350,000
New +$9.2M
FVAM
75
DELISTED
5:01 Acquisition Corp
FVAM
$7.46M 0.11%
750,000
– –
1 2
3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, RA Capital Management held 100 positions worth $6.63B, down 7.3% from $7.15B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

RA Capital Management's Q1 2021 filing shows 18 new, 9 increased, 13 reduced and 18 closed positions. Its largest new stake was Vor Biopharma: 556,049 shares worth $479M. The largest sale was Arvinas, an estimated $312M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials.

  • RA Capital Management's largest Q1 2021 buy was Vor Biopharma: 556,049 shares worth $479M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q1 2021, an estimated $83.1M increase.
  • RA Capital Management's biggest Q1 2021 reduction was TG Therapeutics, cutting an estimated $195M.
  • RA Capital Management fully exited Arvinas in Q1 2021, selling an estimated $312M.
  • RA Capital Management's ten largest holdings make up 50% of its $6.63B portfolio in Q1 2021.
  • RA Capital Management opened 18 new positions and closed 18 in Q1 2021.
  • RA Capital Management's portfolio value fell 7.3% quarter-over-quarter to $6.63B.

Based on RA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.